GlucoTrack, Inc. (GCTK) Fair Value 2026

GCTK · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.6 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (56/100)

Quick Summary — As of 2026-08-28, GlucoTrack, Inc. (GCTK) trades at $0.28. QOC: 3.6/10. Value Trap Risk: 56/100 (WARN). 1/13 models active.

Key Facts

Ticker
GCTK
Price
$0.28
Quality Score
3.6/10
Value Trap Risk
56/100
Models Active
1/13
Last Updated
Strength: Dynamic NAV suggests +404.3% upside with 53% confidence
Risk: Value Trap score of 56 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give GCTK?

1 Intrinsic Value Models vs. Current Price ($0.28)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $1.42 +404.3%

All Models Active

All 1 models are displayed above.

What Is GlucoTrack, Inc. (GCTK) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for GlucoTrack, Inc.. Trading at $0.28 against an estimated intrinsic value of $1.42, 1 of 1 active models flag meaningful upside of +404.3% at the median.

What Do the Models Say About GCTK?

1 of 13 models are currently active for GCTK. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does GCTK Rank in Medical Devices?

Among 159 Medical Devices stocks, GCTK ranks #152 by Quality of Company score. CirclFi's QOC score of 3.6/10 evaluates 32 fundamental signals. A score of 3.6 signals below-average fundamentals.

See all Most Undervalued Medical Devices Stocks →

As a pharmaceutical industry, GlucoTrack, Inc. operates in a sector where R&D productivity ratio is a critical driver of valuation. Investors evaluating GCTK should weigh these sector-specific dynamics alongside our model-derived fair values.

Is GCTK a Value Trap?

CirclFi's Value Trap algorithm assigns GCTK a score of 56/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for GlucoTrack, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, GlucoTrack, Inc.'s fundamental quality profile registers 3.6/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every GCTK valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across GCTK's 1 active models, average confidence is 53%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy GlucoTrack, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

ODYYOdyssey Health, Inc.QOC 3.7LMRILumexa Imaging Holdings, Inc.QOC 3.5STMESTIMCELL ENERGETICS INC.QOC 3.7RTGNRetinalGenix Technologies Inc.QOC 3.5LUDGLudwig Enterprises, Inc.QOC 3.7WOKWORK Medical Technology Group LTDQOC 2.8BIOBio-Rad Laboratories, Inc.QOC 7.8TNDMTandem Diabetes Care, Inc.QOC 6.5NXLNexalin Technology, Inc.QOC 5.6IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: ODYY · LMRI · STME · RTGN · LUDG · WOK · BIO · TNDM · NXL · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to GCTK?

7 companies across all industries closest to GCTK’s Quality of Company score of 3.6/10.

AVATAvalanche Treasury CorporationQOC 3.6HEPAHepion Pharmaceuticals, Inc.QOC 3.6EEGIEline Entertainment Group, Inc.QOC 3.6SSMRSunshine Silver Mining & Refining CompanyQOC 3.6FYNNFyntechnical Innovations Inc.QOC 3.6BENFBeneficientQOC 3.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AVAT · HEPA · EEGI · SSMR · FYNN · BENF · NVDA

Where Does GCTK Sit in CirclFi's Medical Devices Rankings?

GCTK is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About GlucoTrack, Inc.’s Valuation?

What is GlucoTrack, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for GlucoTrack, Inc. (GCTK). The Quality of Company score is 3.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is GCTK overvalued or undervalued right now?

At $0.28, 1 of 1 active models suggest GCTK may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits GlucoTrack, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 3.6 mean for GCTK?

GlucoTrack, Inc.'s QOC of 3.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on GCTK?

CirclFi analyzes GCTK with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is GCTK a value trap in 2026?

GlucoTrack, Inc.'s Value Trap score is 56/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns GlucoTrack, Inc. (GCTK) a Quality of Company score of 3.6/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/GCTK/ · Methodology
Primary sources for this GCTK valuation
  • Financial statements: GlucoTrack, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001506983) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for GCTK as of ; valuations recomputed .